STUDresearch · Non-peptide
S-4 (Andarine)
Also known as
Andarine · S4 · GTx-007
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Some talk
Systemic
Oral
Performance / endurance
Systemic SARM research chem.
What people say
Andarine, or S-4, is an early unapproved SARM known in forums for cutting or recomp claims and distinctive yellow-tint and night-vision reports.
Doses people talk about
These are gray-market self-reports, not a progression. Product identity, stack composition and vision susceptibility vary.
How it may feel
Accounts describe strength, endurance, pumps or a drier look, sometimes not until week 3. Vision reports range from none to yellow or green tint, poor night vision and dark patches on waking.
Broad community oral band~25–50 mg/day oral, often split
The preserved range summarizes discussion; it does not establish a preferred total or protection from vision effects.
Five-to-six-week accounts50 mg/day oral
One five-week account reported intermittent yellow tint and concurrent SR9009; a separate six-week account described severe night-vision and color changes.
Mixed lower-total discussion20–40 mg/day oral across separate reports
Different authors described 20 then 40 mg/day, 30 mg/day split and 37.5 mg/day split, with inconsistent vision effects. These are not one course.
Half-life & effect duration
- Half-life in the body
- Rat studyAbout 2.6–5.3 hours
- Felt duration people report
- Performance reportsStrength or body changes over weeks
- Vision reportsTint or night-vision changes around week 3 in some; absent in others
- PersistenceVision changes can outlast a missed dose or stopping in reports
Cycles people discuss
Six-to-eight-week courses are common in the notes, while actual reports include shorter snapshots. The calendar is community practice, not a validated on/off rule, and vision effects were a prominent reason to stop or reassess.
Timing
Split oral schedules are community practice, not proof of human PK. The roughly 2.6–5.3-hour half-life is preclinical rat data; vision changes may outlast a missed dose without defining parent elimination.
Stacks
Cardarine appears in classic cutting-stack lore, while the notes also say solo accounts are easier to interpret. These are descriptions; combinations add risk and confound both benefits and adverse effects.
Watch for
Vision disturbance: Night vision / yellow tint — hallmark community caution.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No dependable human parent half-life was located.
A rat pharmacokinetic study reported S-4 half-lives of roughly 2.6–5.3 hours under its preclinical dosing conditions. Community split schedules cannot substitute for a human estimate.
Species, dose and formulation differ from gray-market human reports; no validated human parent PK was identified.
- Kearbey et al.: S-4 pharmacokinetics and tissue-selective androgen-receptor modulation (opens in a new tab)Indexed full-text methods/results reviewed for rat pharmacokinetic conditions and the reported 2.6–5.3-hour S-4 half-life range.Preclinical rat evidence; not human pharmacokinetics, not an approved use and not gray-market product validation. Direct PMC page returned a browser verification page during review.
Felt duration people report
No consistent onset or duration covers both performance and vision reports.
Some posters described strength or body-composition changes over weeks; yellow or green tint and night-vision changes appeared around week 3 in some accounts, were absent in others, and could persist beyond a missed dose or after stopping.
Self-selected posts, unverified products, different schedules and co-exposures; lingering vision symptoms are not parent pharmacokinetics.
- First time on Andarine S4 feels like having a permanent filter on my eyes (opens in a new tab)OP and visible same-author replies reviewed: 36-year-old reported 50 mg/day for about five weeks, effects around week 3, intermittent yellow/pale tint, and concurrent SR9009; a couple of missed days did not immediately end vision effects.Unverified products and outcomes, SR9009 co-exposure, no eye testing or controlled timeline; missed-dose persistence is not a parent half-life measurement.
- 6-week S4 Andarine update: pros and cons (opens in a new tab)OP reviewed at week 6 on 50 mg/day: strength, pumps and dryness claims alongside severe night blindness, green tint and dark shadow-like areas on waking.Unverified product and self-report, no ophthalmic assessment, control or clean attribution.
- Andarine S4 community discussion (opens in a new tab)Multiple authors and same-author updates reviewed: separate reports at 30 mg/day split, 37.5 mg/day split, 20 then 40 mg/day and 50 mg/day; vision effects ranged from none to week-3 yellow tint, night blindness and dark areas, with one author reporting resolution over about three weeks after stopping.Multiple unrelated authors cannot be merged; unverified products, incomplete co-exposures and no clinical eye or PK measurements.
What people say
- Hardness / cut look: Classic early SARM anecdotes. anecdote
- Body-comp talk: S-4 (Andarine) is discussed for recomp, strength continuity, or soft-tissue recovery depending on class. forum
- Training confound: PRs and scale changes almost always co-travel with diet phase and programming. anecdote
- Suppression / lipid chatter: Hormonal agents pull bloodwork and PCT conversations even when marketed “mild.” forum
- Cycle thinking: Fixed on/off blocks dominate over indefinite daily use. forum
Doses people talk about
- Community bands: Often ~25–50 mg/day oral, frequently split. Inspected reports at 20–50 mg/day had mixed vision outcomes, so a lower reported total is not proof that vision effects will be absent. forum
- Quality flag: Assume label accuracy only if analytically verified — gray market fill error is common. forum
- Product quality: Gray-market fill accuracy and identity are uncertain; dose math assumes the label is true. forum
- Route changes the math: Oral vs SC vs nasal are not interchangeable milligram-for-milligram stories. forum
- Start conservative (community): When people experiment, they often start at the low end of a charted band to gauge tolerance — still not advice. forum
- Framing: All figures are discussed trial, clinic, or community amounts — research/educational only, not prescriptions. forum
How it may feel
- Days 1–7: The inspected oral reports did not establish a uniform first-week effect. One 50 mg/day account noticed little until roughly week 3; another thread included earlier strength or endurance claims at different split totals. forum
- Weeks 1–2: Vision yellow tint can appear early for some. forum
- Day 1: No inspected account established a characteristic first-dose effect. The useful timing reports concerned changes over days to weeks, especially vision effects emerging around week 3 in some accounts. forum
- Days 2–7: Side-effect window for many agents; benefits, if any, are easy to mis-attribute. forum
- Weeks 1–2: First honest checkpoint in self-logs. forum
Cycles people discuss
- Length: Often 6–8 weeks. forum
- Common pattern: Many self-protocols use weeks-on / weeks-off rather than indefinite daily use — cost and caution drive this more than hard science. forum
- No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
- Reassess: Stop and reassess if adverse effects appear; this is not medical care. forum
Timing
- Split dosing: Two- or three-times-daily schedules appear in community talk, but that practice does not establish a human parent half-life. Published numeric half-lives of roughly 2.6–5.3 hours are from rats, not people. forumtrial
- Timing practicalities: People time doses around side effects, training, and sleep more than perfect PK. forum
- Published PK: Where human PK exists it should override forum half-life memes for S-4 (Andarine). trial
More on what it is
- What it is: Andarine (S-4), early SARM known for vision side-effect lore and cutting/recomp talk. forum
- Research posture: Educational summary of public discussion and literature themes only. forum
- How people talk about it: Forum volume is a popularity signal for S-4 (Andarine), not proof it works for you. forum
- Research only: Not approved advice for self-experimentation; legality and access vary by place. forum
Stacks
- With Cardarine: Classic cut stack lore. forum
- Less is clearer: Solo runs make personal n=1 easier to interpret than five-compound blasts. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Vision disturbance: Night vision / yellow tint — hallmark community caution. forum
- Suppression: Present to varying degrees. forum
- Oral gray-market identity: The inspected accounts relied on labeled research products, not verified clinical andarine. Vision, strength and body-composition reports remain product- and stack-confounded. forum
- Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
- Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
- Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
- Unapproved-drug status: SARMs are not FDA-approved for human use and are not legal dietary-supplement ingredients. This card maps forum talk only — not a sourcing guide, not a safety claim, and not a promise of results. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.